Last reviewed · How we verify
Vaccine produced in existing facility
Vaccine produced in existing facility is a Biologic drug developed by PATH. It is currently FDA-approved.
PATH's vaccine, currently on the market, leverages an existing production facility to maintain a steady supply. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and competitive advantage. The primary risk lies in potential competition once the patent expires, which could erode market share and revenue.
At a glance
| Generic name | Vaccine produced in existing facility |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine produced in existing facility CI brief — competitive landscape report
- Vaccine produced in existing facility updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about Vaccine produced in existing facility
What is Vaccine produced in existing facility?
Who makes Vaccine produced in existing facility?
What development phase is Vaccine produced in existing facility in?
Related
- Manufacturer: PATH — full pipeline
- Compare: Vaccine produced in existing facility vs similar drugs
- Pricing: Vaccine produced in existing facility cost, discount & access